Latest Peptide Research

Name: Latest Peptide Research
Creator: Dr. Scott DelBoccio, DMD

A physician-curated digest of what actually moved in peptide science — new trial readouts, journal publications, and regulatory decisions — translated into plain language and connected to the compounds this site covers. Updated as the literature moves, not as the hype cycle does.

Reviewed by Dr. Scott DelBoccio, DMD·Last updated: September 2026

Hub · Metabolic

Metabolic & Incretin Peptides

The busiest corner of peptide medicine. Incretin-class drugs are producing Phase III readouts and FDA decisions at a pace no other peptide category comes close to.

Jul 2026Phase III readout

Retatrutide clears two more Phase III trials; Lilly signals an FDA filing in early 2027

Eli Lilly announced that TRIUMPH-2 (adults with type 2 diabetes and overweight or obesity) and TRIUMPH-3 (adults with severe obesity and established cardiovascular disease) both met their goals, with weight reductions up to roughly 20.8% and 22.6% respectively at 80 weeks and meaningful A1C improvements. Lilly stated it plans to submit retatrutide to the FDA in the first quarter of 2027. Until that review concludes, retatrutide remains investigational and is legally available only inside Lilly's clinical trials — a point worth remembering given how widely the compound is discussed online. Source: Eli Lilly press release, July 2026.

May 2026Phase III readout

TRIUMPH-1: retatrutide posts the largest weight-loss numbers yet seen in a pivotal obesity trial

Topline results from TRIUMPH-1, the pivotal Phase III obesity trial of Lilly's triple agonist (GIP/GLP-1/glucagon), showed an average weight reduction of 28.3% at 80 weeks in the highest-dose arm, extending to just over 30% in participants who continued treatment through 104 weeks. These are trial-protocol results in monitored participants, not a template for use — but they mark the first time an obesity medication has approached the weight-loss range of bariatric surgery in a Phase III program. Source: Eli Lilly press release, May 2026; covered by AJMC and BioPharma Dive.

Dec 2025FDA approval

FDA approves the first oral GLP-1 pill for weight management

The FDA approved an oral tablet formulation of semaglutide (marketed under the Wegovy name) for chronic weight management, supported by the Phase III OASIS 4 trial. It is the first GLP-1 receptor agonist for obesity that does not require an injection, which matters for patients who are needle-averse and for how broadly this drug class can realistically be prescribed. Source: FDA approval announcement and Novo Nordisk company statement, December 2025.

Dec 2025FDA filing

Novo Nordisk files CagriSema — a GLP-1 plus amylin combination — with the FDA

Novo Nordisk submitted a new drug application for CagriSema, a once-weekly combination of semaglutide and the amylin analogue cagrilintide, for weight management. It is the first GLP-1/amylin combination to reach the FDA's desk and the leading edge of a crowded amylin pipeline (petrelintide, amycretin, and others are behind it). For patients, the takeaway is that the next generation of metabolic peptides is combinations, not single hormones. Source: Novo Nordisk company announcement, December 2025.

Nov 2025Phase III readout — negative

Semaglutide fails to slow early Alzheimer's disease in the evoke trials

Novo Nordisk's evoke and evoke+ trials — the first large Phase III test of a GLP-1 drug in early symptomatic Alzheimer's disease — did not show a slowing of cognitive decline versus placebo. Full results were subsequently published in The Lancet in 2026. This is a useful correction to the "GLP-1s fix everything" narrative: epidemiologic hints do not always survive a randomized trial, and negative results like this one are exactly why we wait for them. Source: Novo Nordisk topline announcement, November 2025; The Lancet, 2026.

Sep 2025CV outcomes trial

SURPASS-CVOT: tirzepatide holds its own against dulaglutide on cardiovascular outcomes

In a head-to-head cardiovascular outcomes trial of more than 13,000 patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior to dulaglutide for major adverse cardiovascular events, with numerically fewer events and better A1C, weight, and kidney-function results. Presented at the European Association for the Study of Diabetes annual meeting in September 2025 with simultaneous journal publication. The significance: tirzepatide's cardiovascular safety story now rests on dedicated outcomes data, not extrapolation. Source: SURPASS-CVOT trial, EASD 2025.

Hub · Repair & Recovery

Repair & Recovery Peptides

The most-searched peptides on this site remain the least-studied in humans. The news here is mostly regulatory — and it matters more than any single study.

Jul 2026FDA advisory action

FDA advisory committee votes 8–6 to recommend BPC-157 for the compounding list

At its July 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding BPC-157 to the list of bulk substances that compounding pharmacies may legally use. The vote is advisory and non-binding — the FDA has not acted on it, and BPC-157 remains unapproved with limited human trial data. If the agency ultimately agrees, prescription compounding would become a legal pathway; it would not make BPC-157 an approved drug, and it would not validate the unregulated products sold online. Source: FDA Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026; reported by ABC News.

2026Phase II trial underway

GHK-Cu gets a real randomized wound-healing trial

A randomized, quadruple-blinded Phase II study (the CuHeal trial, NCT07437586) is enrolling healthy adults to test a topical GHK-Cu gel against placebo on standardized punch-biopsy wounds, measuring time to re-epithelialization and scar quality at 12 weeks. GHK-Cu has decades of laboratory and cosmetic data but very little rigorous human wound-healing evidence, so a properly blinded controlled trial — however small — is genuine progress for this compound. Source: ClinicalTrials.gov registration NCT07437586.

Hub · Longevity & Mitochondrial

Longevity & Mitochondrial Peptides

One peptide in this category crossed the finish line to FDA approval — a first for the field — while the rest remain early-stage science.

Sep 2025FDA approval

Elamipretide becomes the first approved mitochondria-targeted peptide drug

The FDA granted accelerated approval to elamipretide (brand name Forzinity, previously studied as SS-31) for Barth syndrome, an ultra-rare genetic mitochondrial disease — the first approved therapy for the condition and the first mitochondria-targeted peptide to reach approval at all. In the year since, Stealth BioTherapeutics has stood up specialty-pharmacy distribution and a patient support program. Important context: this approval is narrow, for a specific rare disease, and says nothing about elamipretide as a general "longevity" agent. Source: FDA accelerated approval; Stealth BioTherapeutics announcements, September 2025.

2025Preclinical

MOTS-c restores mitochondrial respiration in diabetic heart tissue — in animals

A 2025 study published in Frontiers in Physiology reported that the mitochondria-derived peptide MOTS-c restored mitochondrial respiration in the hearts of type 2 diabetic animal models. It adds to a growing preclinical case that MOTS-c acts as a metabolic signaling peptide, but that is where the evidence still sits: animal and cell data, with no adequately powered human efficacy trials completed. Source: Frontiers in Physiology, 2025.

Hub · Immune

Immune Peptides

Thymosin alpha-1 finally got the large trial its advocates asked for — and the result is a lesson in why big trials matter.

Jan 2025Phase III readout — negative

TESTS trial: thymosin alpha-1 does not reduce sepsis mortality in a 1,106-patient study

The TESTS trial, a multicentre, double-blinded, placebo-controlled Phase III study of 1,106 patients published in The BMJ, found that thymalfasin (thymosin alpha-1) did not significantly reduce 28-day mortality in sepsis (hazard ratio 0.97 after a mid-2025 data correction). Smaller earlier studies had suggested a benefit; the definitive trial did not confirm it. This is the pattern to internalize with immune peptides: promising small studies frequently shrink toward no effect when tested properly. Source: The BMJ, January 2025 (correction May 2025).

2025Trial launched

Thymalfasin heads into a vaccine-response trial in older adults

A registered clinical trial (NCT06821100) is studying thymalfasin as an enhancer of vaccine response in older adults receiving COVID-19 booster doses — a use case that fits the peptide's actual biology as a T-cell modulator better than the broad "immune boosting" claims attached to it in wellness marketing. Results are not yet available; this is a study to watch, not evidence in hand. Source: ClinicalTrials.gov registration NCT06821100.

2025Preclinical

LL-37-derived peptides show activity against multidrug-resistant bacteria

Engineered fragments of the human antimicrobial peptide LL-37 demonstrated activity against multidrug-resistant E. coli and ESKAPE pathogens in laboratory studies published in Scientific Reports, part of a broader 2025 wave of work on LL-37 derivatives as antibiotic-resistance candidates. This is drug-discovery science, not a therapy: the interesting future for LL-37 is as a scaffold for designed antimicrobials, not as an injectable wellness peptide. Source: Scientific Reports, 2025.

Hub · Sexual Health

Sexual Health Peptides

The one approved peptide in this category is now being studied for something else entirely — and organized urology is starting to take the field seriously.

Apr 2026Clinical review

American Urological Association publishes a clinician-facing review of peptides for sexual dysfunction

AUANews, the American Urological Association's member publication, ran an April 2026 review of what clinicians should know about peptides in sexual medicine, covering the approved agent bremelanotide and investigational signals around kisspeptin, whose earlier randomized studies in hypoactive sexual desire disorder came out of Imperial College London. When a major specialty society starts publishing guidance, it signals the topic has moved from fringe to clinic — and that patients should be having these conversations with physicians rather than forums. Source: AUANews, April 2026.

Mar 2025Phase II readout

Bremelanotide crosses over: melanocortin agonist meets its endpoint in an obesity study

Palatin Technologies reported that bremelanotide — approved since 2019 for hypoactive sexual desire disorder in premenopausal women — met the primary endpoint of a Phase II obesity study when co-administered with tirzepatide, producing greater weight reduction than tirzepatide alone over the short 8-week treatment window. It is an early, small study, but it points at the melanocortin-4 receptor as a possible add-on pathway to incretin therapy. Source: Palatin Technologies press release, March 2025.

How to read research news

A few habits will serve you better than any single headline on this page. First, notice who is talking: a company press release is a legal marketing document, and it will always read better than the peer-reviewed paper that follows it months later. I list press-release items here because they move markets and conversations, but I weight them accordingly.

Second, watch for surrogate endpoints. "Improved a biomarker" is not "helped patients live better or longer" — the evoke trials above are a fresh reminder that encouraging signals routinely fail the real test.

Third, single studies almost never change practice. Medicine moves when independent groups replicate a finding in adequately powered trials, and regulators agree. That is slow by design. If a clinic or a seller tells you one new study justifies starting a therapy, that is a sales pitch, not science.

— Dr. Scott DelBoccio, DMD

Frequently Asked Questions

How often is this page updated?

This digest is reviewed and updated as significant developments occur — typically every one to two months, and sooner when a major trial readout or FDA action lands. The "Last updated" date at the top of the page reflects the most recent review. Items are removed or archived when they are superseded by newer data.

Is retatrutide approved yet?

No. As of September 2026, retatrutide is investigational and is legally available only to participants in Eli Lilly's clinical trials. Lilly has announced positive Phase III results from its TRIUMPH program and stated plans to file with the FDA in early 2027, but no regulatory submission has been reviewed or approved. Products sold online as "retatrutide" are not the pharmaceutical drug and are not covered by any of the trial data described here.

Did the FDA approve BPC-157 in 2026?

No. In July 2026 an FDA advisory committee voted 8–6 to recommend adding BPC-157 to the list of substances that compounding pharmacies may use. That vote is non-binding, the FDA has not finalized a decision, and even a favorable final decision would only permit prescription compounding — it would not make BPC-157 an FDA-approved drug, and the human evidence base remains thin.

Do new studies change the site's evidence grades?

Rarely, and deliberately so. A compound's evidence grade on this site reflects the totality of human data — study size, quality, replication, and regulatory review — not the most recent headline. A single positive Phase II study, or a press release without peer review, does not move a grade. Large Phase III readouts, peer-reviewed publications, and FDA actions are the kinds of developments that do.

Can I start one of these peptides based on this research?

Not on the basis of this page. This digest is education, not a treatment recommendation, and it contains no instructions for using any compound. Whether any peptide is appropriate for you depends on your health history, current medications, and goals — a determination only a licensed physician who has examined you can make. Bring this research to that conversation.

Every question on this page ends in the same place.

If something here is relevant to your health, the next step is a conversation with a licensed physician — not a purchase. They can weigh this evidence against your history and tell you what it actually means for you.